Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Citalopram hydrobromide
Drug ID BADD_D00476
Description Citalopram belongs to a class of antidepressant agents known as selective _serotonin-reuptake inhibitors_ (SSRIs) and is widely used to treat the symptoms of depression. Its chemical structure is unrelated to that of other SSRIs or of tricyclic, tetracyclic, or other prescribed antidepressants [FDA label]. Citalopram is also known as _Celexa_, and available in tablet and solution forms [FDA label]. This drug was initially approved by the FDA in 1998 [L5230].
Indications and Usage For the treatment of depression, as indicated by the FDA label [FDA label]. Off-label indications include but are not limited to: treatment of sexual dysfunction, post-stroke behavioural changes, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy [FDA label], [A321], [A322], [A323], [A324], [A174406], [A174409], [A174412].
Marketing Status approved
ATC Code N06AB04
DrugBank ID DB00215
KEGG ID D00822
MeSH ID D015283
PubChem ID 77995
TTD Drug ID D0Y5DO
NDC Product Code 80425-0309; 55700-838; 63187-220; 65862-005; 67296-2041; 71335-0377; 71335-0480; 72789-071; 53104-7738; 59349-0010; 13668-009; 13668-010; 50090-3208; 60760-009; 70934-090; 0615-8022; 0615-8141; 0456-4021; 50090-1298; 50090-6433; 55111-343; 55700-787; 57664-507; 68071-3004; 71610-413; 55154-3329; 70518-0070; 70518-3502; 47621-022; 65862-317; 72761-006; 51655-664; 63187-140; 65862-074; 70518-1357; 70518-1917; 72657-109; 0456-4011; 65862-006; 65862-336; 42708-019; 42708-091; 57664-508; 61919-259; 67296-1186; 68084-737; 68084-744; 68788-0802; 68788-9692; 55111-902; 55486-1572; 13668-011; 43063-481; 65862-007; 70518-0542; 70934-842; 71335-0238; 72657-110; 72657-111; 0904-6085; 51655-605; 51655-680; 53002-1579; 63187-203; 63187-679; 0615-8023; 0904-6084; 0456-4041; 65015-721; 65372-1101; 65372-1130; 65977-0053; 43063-670; 51655-043; 53002-1360; 55111-342; 55700-851; 68788-8962; 71205-764; 64220-105; 65977-0018; 43063-683; 50090-0892; 53002-1359; 53002-2359; 54838-540; 55111-344; 58118-0023; 68645-559; 31722-564; 51655-667; 53002-2360; 55154-3349
UNII I1E9D14F36
Synonyms Citalopram | Cytalopram | Citalopram Hydrobromide | Lu-10-171 | Lu10171 | Seropram | Celexa
Chemical Information
Molecular Formula C20H22BrFN2O
CAS Registry Number 59729-32-7
SMILES CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Disturbance in attention19.21.02.002; 17.03.03.001--
Diverticulitis11.01.07.003; 07.10.02.001--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug dependence19.07.06.011--Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Duodenal ulcer07.04.02.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyskinesia17.01.02.006--
Dysmenorrhoea21.01.01.002--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea02.11.05.003; 22.02.01.004--
Dystonia17.01.03.001--Not Available
Dysuria20.02.02.002--
Ecchymosis23.06.01.001; 01.01.03.001; 24.07.06.002--Not Available
Eczema23.03.04.006--
Ejaculation disorder21.03.01.002--
Electrocardiogram QT prolonged13.14.05.004--
Epistaxis24.07.01.005; 22.04.03.001--
Eructation07.01.02.003--
Erythema multiforme10.01.03.015; 23.03.01.003--
Euphoric mood19.04.02.006--
Extrapyramidal disorder17.01.02.007--
Extrasystoles02.03.02.003--Not Available
Eye pain06.08.03.002--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 9 Pages